National Health (Weighted average disclosed price – second transitional disclosure cycle) Amendment Determination 2012

Instrument number PB 7 of 2012

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the National Health Act 1953.

Dated  20 March 2012

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

 

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

 

1 Name of Determination

 (1) This Determination is the National Health (Weighted average disclosed price – second transitional disclosure cycle) Amendment Determination 2012.

 (2) This Determination may also be cited as PB 7 of 2012.

2 Commencement

  This Determination commences on the day after it is registered.

 

 

3 Amendments to PB 82 of 2011

Schedule 1 amends the National Health (Weighted average disclosed price – second transitional disclosure cycle) Determination 2011 (PB 82 of 2011).

Schedule 1    Amendments

 

[1]  Schedule 1, After

 

76

Gemcitabine

Solution concentrate for I.V. infusion 500 mg (as hydrochloride) in 50 mL

Injection

Gemcitabine Ebewe

30.41

32.70

 

 

 insert:

 

76A

Gemcitabine

Solution concentrate for I.V. infusion 1g (as hydrochloride) in 25 mL

Injection

Gemcitabine Ebewe

60.81

65.38

76B

Gemcitabine

Solution concentrate for I.V. infusion 2 g (as hydrochloride) in 50 mL

Injection

Gemcitabine Ebewe

121.90

131.07

76C

Gemcitabine

Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 5 mL

Injection

Gemcitabine Ebewe

12.31

13.24

                  76D

Gemcitabine

Solution for injection 1 g (as hydrochloride) in 26.3 mL

Injection

DBL Gemcitabine Injection

 

60.81

65.38

76E

Gemcitabine

Solution for injection 2 g (as hydrochloride) in 52.6 mL

Injection

DBL Gemcitabine Injection

121.90

131.07

76F

Gemcitabine

Solution for injection 200 mg (as hydrochloride) in 5.3 mL

Injection

DBL Gemcitabine Injection

12.31

13.24

 

 

 

 

 

 

[2]  Schedule 1, After

 

96

Irinotecan

I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL

Injection

Irinotecan Actavis 500

194.45

209.07

 

 

             insert:

 

96A

Irinotecan

I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL

Injection

Tecan

194.45

209.07

 

 

Note

1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.